On June 11, 2026, the U.S. Food and Drug Administration (FDA) announced the issuance of an Emergency Use Authorization (EUA) for generic Nitenpyram Tablets (nitenpyram) to treat New World screwworm (NWS) infestations, also known as myiasis, in dogs and cats weighing at least two pounds and older than four weeks.
NWS, a severe parasitic condition caused by the larvae of the Cochliomyia hominivorax fly, poses significant health risks to affected animals. The larvae feed on the tissues of the host, leading to severe pain, infections, and in severe cases, death. The current infestation of NWS in various regions underscores the importance of rapid interventions for pet health.
The FDA’s decision to authorize the use of Nitenpyram, a previously available oral medication initially approved for the treatment of fleas, reflects the agency's commitment to providing timely solutions for emerging veterinary health threats. This authorization comes amid increasing concerns regarding NWS outbreaks, which can jeopardize not only animal health but also public health given the potential for spread in both wild and domesticated animal populations.
Veterinary professionals should be aware of this new development and consider the role of Nitenpyram in treating NWS in at-risk pets. While the drug has a history of use in similar contexts, practitioners are reminded to closely monitor dosage and potential side effects. Its applicability in non-traditional veterinary settings also warrants discussion among professionals in the field.